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Over a 27-year period there were 15 patients treated at the 
University of Michigan Medical center for carcinosarcomas or 
mixed mesodermal tumors of the ovary. Overall median survival 
was 11 months. Median survival was 4 months in patients with 
carcinosarcomas and 13 months in patients with mixed mesodermal 
tumors (P = 0.066). Patients with a chondrosarcomatous element 
had a significantly longer median survival than patients with 
mixed mesodermal tumors lacking cartilaginous differentiation 
(P = 0.031). The presence of a rhabdomyosarcomatous element 
did not affect survival. The size of the primary tumor, presence 
of ascites, FIGO stage, and degree of initial resection (optimal 
versus suboptimal) did not affect survival. There was no difference 
in survival between patients receiving postoperative chemotherapy 
and patients undergoing postoperative irradiation. © 1989 Academic 
Press, Inc. 
INTRODUCTION 
Malignant mixed mesodermal tumors and carcinosar- 
comas of the ovary are unusual and constitute less than 
1% of all ovarian malignancies [1]. 
These tumors are composed of intimately admixed car- 
cinomatous and sarcomatous components. Tumors con- 
taining a "heterologous" element, i.e., chondrosarcoma 
or rhabdomyosarcoma, are termed mixed mesodermal 
tumors; if heterologous differentiation is absent the ovarian 
tumor is termed carcinosarcoma. These tumors have been 
noted to be aggressive and rapidly progressive; the only 
effective therapy has been surgical resection of localized 
disease [2,3]. The majority of patients, however, present 
with tumor extending beyond the ovary and require ad- 
ditional treatment. The present study was undertaken to 
review the clinicopathologic features, treatment, and out- 
come of patients with mixed mesodermal tumors and 
carcinosarcomas of the ovary. 
MATERIALS AND METHODS 
The medical records of all patients presenting to the 
University of Michigan Medical Center with carcinosar- 
comas or mixed mesodermal tumors of the ovary from 
1959 to 1986 were retrospectively reviewed. Clinical fea- 
tures, surgical findings, treatment, and follow-up were 
all reviewed in detail. All histologic materials were re- 
viewed by one of the primary authors (T.L.J.). Four 
patients who had been previously reported [3], however, 
were included in the present report to further analyze 
treatment outcome and histopathology. Tissue blocks were 
recut for special stains, including periodic acid-Schiff 
(PAS) and ~-l-antitrypsin. 
Survival was calculated using the product-limit method 
of Kaplan and Meier [4]. Gehan's generalized Wilcoxon 
test was used to compare survival distributions [5]. 
RESULTS 
There were 15 patients treated during this period for 
carcinosarcomas or mixed mesodermal tumors of the 
ovary. Patients were all white with a mean age of 63 
years (range 44-72 years). Mean parity was 3.1 with 13% 
of patients nulliparous. One patient had undergone prior 
hysterectomy for a benign condition and 1 patient had 
undergone prior radiotherapy for a squamous cell car- 
cinoma of the cervix. One patient had concomitant en- 
dometriosis, and 1 patient had a simultaneous well-dif- 
ferentiated adenocarcinoma of the endometrium. 
The majority of patients presented with nonspecific 
symptoms characteristic of ovarian tumors: Increased 
abdominal girth, bloating, fatigue, and lower abdominal 
discomfort. One patient was asymptomatic at the time 
of presentation. 
All patients underwent an initial laparotomy. Operative 
findings revealed ovarian tumors from 3 to 25 cm in 
diameter; tumor size averaged 15 cm. Seven cases involved 
both ovaries, six involved the right ovary only and two 
arose in the left ovary. The neoplasms were usually solid 
and cystic with areas of hemorrhage and necrosis. Solid 
areas often had a fleshy consistency and were variegated 
in appearance. Nine patients had ascites, including 2 
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patients with bloody ascites. All patients had tumor ex- 
tending beyond the ovary; 4 patients were FIGO stage 
II and 11 patients were FIGO stage III. Sites of metastases 
involved the omentum, peritoneum, serosal surfaces, and 
pelvic soft tissue. In 5 patients an optimal cytoreductive 
operation was accomplished (residual tumor less than 
1.5 cm in greatest diameter). Ten patients were left with 
suboptimal disease. 
Following initial surgery, one patient had no further 
treatment. Five patients underwent pelvic irradiation and 
one patient underwent abdominopelvic irradiation. Eight 
patients received chemotherapy. Chemotherapeutic reg- 
imens varied considerably; however, they consisted of 
either a single alkylating agent (melphalan or chlorambucil) 
or combinations utilizing vincristine, actinomycin D, cy- 
clophosphamide, Adriamycin, cis-platinum, methotrexate, 
and/or dacarbazine. The most frequently used combination 
was vincristine, actinomycin D, and cyclophosphamide. 
Neoplasms were classified as mixed mesodermal tumors 
if they contained both a carcinomatous component and 
a sarcomatous component with foci of chondrosarcoma, 
rhabdomyosarcoma, osteosarcoma, and/or liposarcoma. 
Carcinosarcomas contained a malignant epithelial corn- 
ponent and a sarcomatous component without differ- 
entiation toward cartilage, skeletal muscle, bone, or adi- 
pose tissue. 
In all of the ovarian tumors, the malignant epithelial 
component was moderately to poorly differentiated ad- 
enocarcinoma. The proportion of carcinoma present in 
the tumors ranged from 10% to 95%. Ten of the tumors 
(67%) had a predominantly papillary adenocarcinomatous 
component while in five cases (33%) the adenocarcinoma 
had a predominantly glandular growth pattern which re- 
sembled endometrioid carcinoma. All of the neoplasms 
had areas of adenocarcinoma with a solid growth pattern. 
Generally, the pattern of adenocarcinoma present in the 
primary tumor was also present in metastatic and recurrent 
tumors, although in several cases the degree of differ- 
entiation decreased and the proportion of solid growth 
pattern was greater in the metastatic tumors. In one 
patient, metastases had an adenosquamous component 
(Fig. 1) while the primary ovarian tumor had a pure 
adenocarcinoma component with a glandular growth 
pattern. 
Eleven tumors contained areas of chondrosarcoma or 
rhabdomyosarcoma and were therefore classified as mixed 
FIG. 1. Foci of adenosquamous carcinoma in area of undifferentiated sarcoma. H & E, × 16. 
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FIG. 2. Glandular adenocarcinoma (left and mid-upper) with focus of chondrosarcoma (right lower) in area of undifferentiated sarcoma. H 
& E ,  x l0 .  
mesodermal tumors of ovary (Fig. 2). There were no foci 
of osteosarcoma or liposarcoma in any of the neoplasms. 
Six tumors contained chondrosarcoma, 2 contained rhab- 
domyosarcoma, and 3 contained both components. The 
foci of rhabdomyosarcoma were identified in H & E- 
stained slides as large eosinophilic polygonal or strap- 
shaped cells with large eccentric nuclei and prominent 
nucleoli. Immunoperoxidase stains for desmin and myo- 
globin were done to confirm the presence of rhabdo- 
myoblasts. In all of the mixed mesodermal tumors, the 
areas of chondrosarcoma and rhabdomyosarcoma ac- 
counted for less than 50% of the sarcomatous component. 
Most of the sarcomatous areas were composed of un- 
differentiated and myxoid sarcoma, similar to the non- 
epithelial component in the four carcinosarcomas. The 
areas of undifferentiated sarcoma in both the mixed me- 
sodermal tumors and the carcinosarcomas contained an- 
aplastic spindle-cells with a very high mitotic rate including 
abnormal forms and many bizzare, pleomorphic tumor 
giant cells. The myxoid sarcoma areas were less cellular 
than the undifferentiated sarcoma and were composed 
of spindle cells in a basophilic myxohyaline background 
(Fig. 3). Mitotic figures and giant cells were less numerous 
in the areas of myxoid sarcoma. PAS-positive, diastase- 
resistant hyaline droplets which stained with o~-antitrypsin 
were present in the sarcomatous areas of 80% of the 
tumors. 
Median overall survival was 11 months and was not 
affected by stage, optimal versus suboptimal initial re- 
section, size of the primary tumor, or the presence of 
ascites. The mean progression free interval was 8 months 
and the mean survival following recurrence was 3 months. 
There was no significant difference in survival between 
patients receiving chemotherapy and patients undergoing 
postoperative irradiation. In addition, there was no 
chemotherapeutic agent or regimen that appeared more 
efficacious than the others. 
Median survival was 4 months in patients with car- 
cinosarcomas and 13 months in patients with mixed me- 
sodermal tumors. This difference was of borderline sta- 
tistical significance (P = 0.066). Patients with a 
chondrosarcomatous element had a significantly longer 
median survival (13 months) than patients with mixed 
mesodermal tumors lacking cartilaginous differentiation 
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FIG. 3. Myxoid sarcoma with pleomorphic tumor giant cells. H & E, x25. 
(6 months, P = 0.031). The presence or absence of a 
rhabdomyosarcomatous element did not significantly affect 
survival. 
Patients developing recurrent disease presented with 
a mass in the abdomen and/or pelvis (11 patients) or 
ascites (3 patients). All patients with recurrence died of 
disease. Five patients underwent postmortem examination. 
Two patients had both carcinomatous elements and sar- 
comatous elements present. Three patients had only sar- 
comatous elements identified microscopically at post- 
mortem examination. All 5 patients had tumor confined 
to the abdomen and pelvis and had tumor extensively 
involving the intraabdominal organs. Sites of metastases 
are noted in Table 1. 
DISCUSSION 
Mixed mesodermal tumors and carcinosarcomas of the 
ovary are unusual tumors, with less than 300 cases reported 
in the literature [2,6]. This study confirms previous reports 
that these malignancies are rapidly progressive and almost 
uniformly fatal [7-10]. Clinically, presenting symptoms 
and physical signs are characteristic of ovarian malig- 
nancies, i.e, bloating, fatigue, increased abdominal girth, 
etc. Although nulliparity and endometriosis have both 
been associated with these malignancies, endometriosis 
was noted in only one patient and nulliparity in two 
patients in the present series. One patient in the series 
had undergone prior pelvic radiotherapy. A review of 
the literature indicates that endometriosis and/or prior 
radiotherapy are probably not significant etiologic factors 
in this disease [2,11]. 
TABLE 1 
Sites of Metastases at  Pos tmor tem Examina t ion ,  Five Pat ients  
Sites Number of patients 
Peritoneal, serosal surfaces 5 
Liver 3 
Diaphragm 3 
Periaortic lymph nodes 4 
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Operative findings and patterns of metastases generally 
resemble that found with epithelial ovarian carcinomas. 
Metastases most often involve the peritoneal and serosal 
surfaces and pelvic soft tissues. None of the patients had 
gross involvement of the retroperitoneal lymph nodes at 
the time of initial laparotomy; however, these were not 
routinely biopsied. Retroperitoneal lymph nodes were a 
common site of metastases at postmortem examination. 
Therefore, a careful and complete initial staging procedure 
is recommended as for patients with epithelial 
malignancies. 
In the present study stage did not appear to affect 
survival. All patients, however, had tumor extension be- 
yond the ovary. Previous reports indicate that patients 
presenting with earlier stages may have a slightly better 
prognosis [7,10]; and surgical resection of tumor limited 
to one ovary appears to represent the most realistic chance 
of long-term survival [3,10]. 
Fourteen of 15 patients in this series received additional 
treatment following surgery. As with previous studies 
there was no chemotherapeutic agent or regimen that 
appeared clearly superior [12]. In addition, survival with 
postoperative radiotherapy was not significantly different 
than with chemotherapy. Other reports indicate that 
postoperative treatment with combined radiotherapy- 
chemotherapy may occasionally be effective in achieving 
long-term remission [13,14]. 
The most significant histopathologic variable in the 
present study was the presence of a chondrosarcomatous 
component in patients with mixed mesodermal tumors. 
These patients had a significantly longer median survival 
than patients without cartilaginous differentiation. There 
was no significant difference in survival between patients 
with carcinosarcomas and mixed mesodermal tumors. 
Dehner et al. reported a longer median survival in patients 
with carcinosarcomas than patients with mixed meso- 
dermal tumors; their population, however, contained a 
greater proportion of early stage lesions in patients with 
carcinosarcomas [8]. Stage and stromal type appear to 
be interrelated prognostic determinants [8,10]; with ad- 
vanced stage disease there may not be a significant dif- 
ference in survival. 
The presence of PAS-positive, diastase-resistant hyaline 
droplets staining positive for a-antitrypsin was noted in 
a majority of the tumors. Although this has been noted 
previously, the clinical significance remains unclear [15]. 
The possibility of utilizing serum levels of a-antitrypsin 
as a tumor marker should be investigated in the future. 
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